NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.
Further, Oncopeptides AB (publ) is notified that stabilisation measures have been effected in the Company’s shares on Nasdaq Stockholm. The stabilisation period has now ended and no further stabilisation transactions will be effected.
For more information please visit: www.oncopeptides.se
This information is such that Oncopeptides is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on 24 March 2017 at 7.30 p.m (CET).